Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 82 (3), 178-183

Pharmacokinetics of Cannabidiol Administered by 3 Delivery Methods at 2 Different Dosages to Healthy Dogs

Affiliations
Randomized Controlled Trial

Pharmacokinetics of Cannabidiol Administered by 3 Delivery Methods at 2 Different Dosages to Healthy Dogs

Lisa R Bartner et al. Can J Vet Res.

Abstract

The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.

Figures

Figure 1
Figure 1
Single-dose cannabidiol (CBD) plasma concentration. The 12-hour, single-dose CBD plasma concentration (mean +/− standard deviation) at 2 different dosages (75 mg, top; 150 mg, bottom) for transdermal cream, microencapsulated oil beads, and CBD-infused oil.
Figure 2
Figure 2
Cannabidiol (CBD) concentration at 6 wk. Maximal CBD plasma concentrations (mean +/− standard deviation) after twice-daily dosing for 2, 4, or 6 wk using 3 formulations. The lower dose (75 mg q12h) is represented on the left and the higher dose (150 mg q12h) on the right.

Similar articles

See all similar articles

Cited by 4 articles

Publication types

LinkOut - more resources

Feedback